Literature DB >> 29671242

Fbxw7β is an inducing mediator of dexamethasone-induced skeletal muscle atrophy in vivo with the axis of Fbxw7β-myogenin-atrogenes.

Kyungshin Shin1,2, Young-Gyu Ko3, Jaemin Jeong4, Heechung Kwon5,6.   

Abstract

Muscle atrophy is induced by several pathways, e.g., it can be attributed to inherited cachectic symptoms, genetic disorders, sarcopenia, or chronic side effects of treatments. However, the underlying regulatory mechanisms that contribute to muscle atrophy have not been fully elucidated. In this study, we evaluated the role of Fbxw7β, an ubiquitin E3 ligase, in a dexamethasone-induced muscle atrophy model. In this model, endogenous Fbxw7β was up-regulated; furthermore, the Fbxw7β-myogenin-atrogene axis was upregulated, supporting our previous results linking Fbxw7β to muscle atrophy in vitro. Also, muscle atrophy was associated with the Fbxw7β-myogenin-atrogene axis and the down-regulation of Dach2, a repressor of myogenin. Taken together, these results suggest that the ubiquitin E3 ligase Fbxw7β and the Fbxw7β-myogenin-atrogene axis have important roles in a dexamethasone-induced muscle atrophy model in vivo and in vitro. Additionally, the Fbxw7β-Dach2-myogenin-atrogene axis is a potential mechanism underlying muscle atrophy in cases of abnormal Fbxw7β expression-induced muscle atrophy or myogenic degenerative disease.

Entities:  

Keywords:  Atrogenes; Dach2; Dexamethasone; Fbxw7β; Myogenin; Skeletal muscle atrophy

Mesh:

Substances:

Year:  2018        PMID: 29671242     DOI: 10.1007/s11033-018-4185-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  24 in total

Review 1.  Mechanisms of glucocorticoid-induced myopathy.

Authors:  O Schakman; H Gilson; J P Thissen
Journal:  J Endocrinol       Date:  2008-04       Impact factor: 4.286

2.  Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases.

Authors:  Viviana Moresi; Andrew H Williams; Eric Meadows; Jesse M Flynn; Matthew J Potthoff; John McAnally; John M Shelton; Johannes Backs; William H Klein; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Cell       Date:  2010-10-01       Impact factor: 41.582

3.  Myogenin regulates denervation-dependent muscle atrophy in mouse soleus muscle.

Authors:  Peter C D Macpherson; Xun Wang; Daniel Goldman
Journal:  J Cell Biochem       Date:  2011-08       Impact factor: 4.429

4.  Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.

Authors:  Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni
Journal:  Age Ageing       Date:  2010-04-13       Impact factor: 10.668

5.  IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1.

Authors:  Jennifer M Sacheck; Akira Ohtsuka; S Christine McLary; Alfred L Goldberg
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-04-20       Impact factor: 4.310

6.  The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.

Authors:  Julie Lagirand-Cantaloube; Nicolas Offner; Alfredo Csibi; Marie P Leibovitch; Sabrina Batonnet-Pichon; Lionel A Tintignac; Carlos T Segura; Serge A Leibovitch
Journal:  EMBO J       Date:  2008-03-20       Impact factor: 11.598

7.  Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics".

Authors:  M Muscaritoli; S D Anker; J Argilés; Z Aversa; J M Bauer; G Biolo; Y Boirie; I Bosaeus; T Cederholm; P Costelli; K C Fearon; A Laviano; M Maggio; F Rossi Fanelli; S M Schneider; A Schols; C C Sieber
Journal:  Clin Nutr       Date:  2010-01-08       Impact factor: 7.324

Review 8.  Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment.

Authors:  Nagi B Kumar; Aslam Kazi; Tiffany Smith; Theresa Crocker; Daohai Yu; Richard R Reich; Kiran Reddy; Sally Hastings; Martine Exterman; Lodovico Balducci; Kyle Dalton; Gerold Bepler
Journal:  Curr Treat Options Oncol       Date:  2010-12

9.  Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1.

Authors:  Abigail S McElhinny; Kazumi Kakinuma; Hiroyuki Sorimachi; Siegfried Labeit; Carol C Gregorio
Journal:  J Cell Biol       Date:  2002-04-01       Impact factor: 10.539

10.  Myostatin suppression of Akirin1 mediates glucocorticoid-induced satellite cell dysfunction.

Authors:  Yanjun Dong; Jenny S Pan; Liping Zhang
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more
  1 in total

1.  Differences in the Role of HDACs 4 and 5 in the Modulation of Processes Regulating MAFbx and MuRF1 Expression during Muscle Unloading.

Authors:  Ekaterina P Mochalova; Svetlana P Belova; Tatiana Y Kostrominova; Boris S Shenkman; Tatiana L Nemirovskaya
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.